MK-0941

• CAT Number: I008043
• CAS Number: 1137916-97-2
• Molecular Formula: C22H28N4O9S2
• Molecular Weight: 556.61
• Purity: ≥95%
• Synonyms: 3-(6-ethylsulfonylpyridin-3-yl)oxy-5-[(2S)-1-hydroxypropan-2-yl]oxy-N-(1-methylpyrazol-3-yl)benzamide;methanesulfonic acid
• IUPAC Name: 3-[(6-ethylsulfonyl-3-pyridinyl)oxy]-5-[(2S)-1-hydroxypropan-2-yl]oxy-N-(1-methylpyrazol-3-yl)benzamide;methanesulfonic acid
• InChI: InChI=1S/C21H24N4O6S.CH4O3S/c1-4-32(28,29)20-6-5-16(12-22-20)31-18-10-15(9-17(11-18)30-14(2)13-26)21(27)23-19-7-8-25(3)24-19;1-5(2,3)4/h5-12,14,26H,4,13H2,1-3H3,(H,23,24,27);1H3,(H,2,3,4)/t14-;/m0./s1
• InChIKey: PIDNRTWDGDJKSQ-UQKRIMTDSA-N
• SMILES: CCS(=O)(=O)C1=NC=C(C=C1)OC2=CC(=CC(=C2)C(=O)NC3=NN(C=C3)C)O[C@@H](C)CO.CS(=O)(=O)O

MK-0941（Cat No.:I008043）is an experimental glucokinase activator (GKA) developed for type 2 diabetes management. Glucokinase acts as a glucose sensor in pancreatic β-cells and liver, regulating insulin secretion and glucose uptake. By enhancing glucokinase activity, MK-0941 aimed to improve glycemic control and reduce hyperglycemia. Early studies showed glucose-lowering effects, but later clinical trials revealed limitations, including waning efficacy and increased risk of hypoglycemia. These drawbacks halted its clinical development. Despite this, MK-0941 helped advance understanding of glucokinase activators as potential metabolic disease therapies.